New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
07:47 EDTDVAXDynavax a compelling buy at current levels, says Jefferies
Jefferies views Dynavax as a risky but compelling buy at current levels following the negative FDA panel vote on the company's hepatitis B vaccine. The firm lowered its price target for shares to $5 from $5 and keeps a Buy rating on the stock.
News For DVAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
06:02 EDTDVAXDynavax completes enrollment of HEPLISAV-B Phase 3 study
Dynavax Technologies announced completion of planned enrollment in the ongoing phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. More than 8,250 adults, including over 1,100 diabetic subjects, have been enrolled at 40 sites in the U.S. This large safety and immunogenicity study is intended to provide an adequately-sized database of vaccinated subjects to enable the FDA to complete its review of the pending HEPLISAV-B Biologics License Application. The study is also designed to assess the immunogenicity of HEPLISAV-B in adults for whom approved hepatitis B vaccines are less effective, including those with type-2 diabetes mellitus.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use